HLA-A*0201-Restricted VEGFR1 Peptide Vaccine
DRACPC ID DRACPC0094
Active Ingredients HLA-A*0201-Restricted VEGFR1 Peptide Vaccine
Description A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
Synonyms VEGFR1-A2-770; HLA-A*0201-Restricted VEGFR1 Peptide Vaccine
Type Biotech
Disease Advanced Pancreatic Cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence TLFWLLLTL
Sequence Length 9
Modification None
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number Not available
NCI Thesaurus Code C77878
UNII Not available
CAS Not available
Drug approval
Drug indication
Investigated for use/treatment in Advanced Pancreatic Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00683085 | Phase I/II Trial of Human Leukocyte Antigen (HLA)-A*02:01-restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination Combined With Conventional Dose of Gemcitabine for Advanced Pancreatic Cancer | Pancreatic Cancer; Pancreas Neoplasms | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
